NP10679

DRUG2 trials

Sponsors

Neurop Inc.

Conditions

Pain, PostoperativeSafety IssuesStroke, IschemicSubarachnoid HemorrhageSubstance Abuse

Phase 1

Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

CompletedNCT03565861

Neurop Inc.Safety Issues

Start: 2018-04-06End: 2018-10-10Updated: 2019-03-13

A Multiple Ascending Dose Study of Safety and Pharmacokinetics of NP10679 in Normal Healthy Volunteers

CompletedNCT04007263

Neurop Inc.Pain, Postoperative, Stroke, Ischemic, Subarachnoid Hemorrhage +1

Start: 2019-04-04End: 2019-10-10Updated: 2019-11-04

Related Papers

Phase 1 Clinical Results for NP10679, a pH‐sensitive GluN2B‐selective <i>N</i>‐methyl‐<scp>d</scp>‐aspartate Receptor Inhibitor

Clinical Pharmacology in Drug Development2023-01-157 citations